Loading...

Home
Stock
NVSEF

NVSEF News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Forecast Technical Valuation Financials Earnings News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
News Release

Market

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks

Strategies

AI Stock Picker
Swing Trading
QuantAI Alpha Pick
CoinSwing
Daytrading Radar
Crypto Radar
Char Pattern Detection

Resource

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat with Tia
AI Screener
Backtesting Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Option Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Monitor News

Compare

TradingView
Seeking Alpha

NVSEF News

One in Four Metastatic Breast Cancer Patients on Novartis Kisqali® Stay Progression-Free for Over Four Years

Dec 09 2025Yahoo Finance

Novartis Highlights Groundbreaking Scientific Advances in Hematology and Oncology at ASH and SABCS

Nov 25 2025Yahoo Finance

Novartis Unveils New Data at ASN Kidney Week and AHA Scientific Sessions Highlighting Progress in CRM Portfolio and Pipeline

Nov 04 2025Yahoo Finance

Novartis' Cosentyx® Achieves Primary and All Secondary Endpoints in Phase III Trial for Polymyalgia Rheumatica (PMR) Patients

Oct 22 2025Yahoo Finance

Novartis Announces Encouraging Fabhalta Findings in IgAN

Oct 16 2025Yahoo Finance

Novartis Fabhalta® (iptacopan) achieves Phase III primary goal, reduces kidney function decline in IgA nephropathy (IgAN) patients.

Oct 16 2025Yahoo Finance

Novartis CEO Considering U.S. Price Reductions as Trump’s MFN Deadline Approaches

Sep 20 2025SeekingAlpha

Novartis and Argo Collaborate on Cardiovascular Assets in a Deal Valued at Up to $5.2 Billion

Sep 03 2025SeekingAlpha

NVSEF Events

an image of No data

No data

NVSEF Monitor News

an image of No data

No data

NVSEF Earnings Analysis

an image of No Data

No Data

People Also Watch